Literature DB >> 27284413

Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines.

Yuan Jian1, Yuling Chen2, Chuanying Geng1, Nian Liu1, Guangzhong Yang1, Jinwei Liu1, Xin Li1, Haiteng Deng2, Wenming Chen1.   

Abstract

Recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand (rmhTRAIL) has become a potential therapeutic drug for multiple myeloma (MM). However, the exact targets and resistance mechanisms of rmhTRAIL on MM cells remain to be elucidated. The present study aimed to investigate the target and resistance-related proteins of rmhTRAIL on myeloma cell lines. A TRAIL-sensitive myeloma cell line, RPMI 8226, and a TRAIL-resistance one, U266, were chosen and the differentially expressed proteins between the two cell lines were analyzed prior and subsequent to rmhTRAIL administration by a liquid chromatography-tandem mass spectrometry method. The results showed that following TRAIL treatment, 6 apoptosis-related proteins, calpain small subunit 1 (CPNS1), peflin (PEF1), B-cell receptor-associated protein 31 (BAP31), apoptosis-associated speck-like protein containing CARD (ASC), BAG family molecular chaperone regulator 2 (BAG2) and chromobox protein homolog 3 (CBX3), were upregulated in RPMI 8226 cells while no change was identified in the U266 cells. Furthermore, small ubiquitin-related modifier 1 and several other ubiquitin proteasome pathway (UPP)-related proteins expressed higher levels in TRAIL-resistant cells U266 compared to the RPMI-8226 cells prior and subsequent to rmhTRAIL treatment. These results suggested that CPNS1, PEF1, BAP31, ASC, BAG2 and CBX3 were possibly target proteins of rmhTRAIL on RPMI 8226 cells, while UPP may have a vital role in mediating TRAIL-resistance in U266 cells.

Entities:  

Keywords:  multiple myeloma; proteomics; recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand; resistant-related protein; target protein

Year:  2016        PMID: 27284413      PMCID: PMC4887918          DOI: 10.3892/br.2016.650

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  21 in total

Review 1.  The proteomics of keratin proteins.

Authors:  Jeffrey E Plowman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-08-22       Impact factor: 3.205

2.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Authors:  C S Mitsiades; S P Treon; N Mitsiades; Y Shima; P Richardson; R Schlossman; T Hideshima; K C Anderson
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

Review 3.  The clinical trail of TRAIL.

Authors:  E W Duiker; C H Mom; S de Jong; P H B Willemse; J A Gietema; A G J van der Zee; E G E de Vries
Journal:  Eur J Cancer       Date:  2006-08-01       Impact factor: 9.162

4.  TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells.

Authors:  Y Gazitt
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

Review 5.  Multiple myeloma.

Authors:  Jean-Luc Harousseau; John Shaughnessy; Paul Richardson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

6.  The receptor for the cytotoxic ligand TRAIL.

Authors:  G Pan; K O'Rourke; A M Chinnaiyan; R Gentz; R Ebner; J Ni; V M Dixit
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

7.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling.

Authors:  G Pan; J Ni; G Yu; Y F Wei; V M Dixit
Journal:  FEBS Lett       Date:  1998-03-06       Impact factor: 4.124

8.  Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Fang Fang; Ai-ping Wang; Shi-fang Yang
Journal:  Acta Pharmacol Sin       Date:  2005-11       Impact factor: 6.150

9.  A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.

Authors:  Chuanying Geng; Jian Hou; Yaozhong Zhao; Xiaoyan Ke; Zhao Wang; Lugui Qiu; Hao Xi; Fuxu Wang; Na Wei; Yan Liu; Shifang Yang; Peng Wei; Xiangjun Zheng; Zhongxia Huang; Bing Zhu; Wen-Ming Chen
Journal:  Am J Hematol       Date:  2014-09-29       Impact factor: 10.047

Review 10.  Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysis.

Authors:  Adam T Melvin; Gregery S Woss; Jessica H Park; Marcey L Waters; Nancy L Allbritton
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

View more
  4 in total

1.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

2.  Fucoxanthin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Synergistically Promotes Apoptosis of Human Cervical Cancer Cells by Targeting PI3K/Akt/NF-κB Signaling Pathway.

Authors:  Ye Jin; Shuang Qiu; Na Shao; Jianhua Zheng
Journal:  Med Sci Monit       Date:  2018-01-01

3.  BAG2 Overexpression Correlates with Growth and Poor Prognosis of Esophageal Squamous Cell Carcinoma.

Authors:  Ying-Cai Hong; Zheng Wang; Bin Peng; Li-Gang Xia; Lie-Wen Lin; Zheng-Lei Xu
Journal:  Open Life Sci       Date:  2018-12-31       Impact factor: 0.938

4.  Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.

Authors:  Tongyou Sun; Tienian Zhu; Xiujun Liang; Shifang Yang; Ruijing Zhao
Journal:  Med Sci Monit       Date:  2018-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.